Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
A 2025 peer-reviewed study analyzing 341 Phase 3 pivotal trials supporting FDA approvals from 2017 to 2023 found that only 6% achieved enrollment aligned with the population distribution of the four largest US racial and ethnic groups
Set expectations accordingly: BPC-157 is a promising tool for knee rehabilitation, not a proven therapy
HUBERMAN: The other category, which I'm going to call category two, you'll also hear a lot about, and they operate a little bit differently
Still Deciding
Studies show it works too - a six-month trial noted higher levels of glutathione (GSH) in blood, lymphocytes, and cells, and demonstrated reduced oxidative stress as a result of supplementation
Ukropec J et al
US$ 25.81
US$ 26.17
US$ 21.16
US$ 23.76
US$ 22.58
US$ 27.33
US$ 22.07
US$ 27.22
US$ 26.76
